S&P 500   4,579.02 (+0.26%)
DOW   34,489.97 (+0.02%)
QQQ   394.63 (+0.21%)
AAPL   168.03 (+1.65%)
MSFT   334.87 (+1.29%)
FB   317.19 (-2.24%)
GOOGL   2,876.81 (+1.37%)
AMZN   3,490.12 (-0.48%)
TSLA   1,135.00 (-0.85%)
NVDA   321.98 (-1.46%)
BABA   124.98 (-2.00%)
NIO   39.45 (+0.82%)
CGC   10.27 (-4.11%)
AMD   152.20 (-3.90%)
GE   95.14 (+0.16%)
MU   87.07 (+3.65%)
T   22.44 (-1.71%)
F   19.94 (+3.91%)
DIS   144.58 (-0.22%)
PFE   54.82 (+2.03%)
ACB   6.18 (-3.74%)
AMC   31.07 (-8.46%)
BA   192.97 (-2.47%)
S&P 500   4,579.02 (+0.26%)
DOW   34,489.97 (+0.02%)
QQQ   394.63 (+0.21%)
AAPL   168.03 (+1.65%)
MSFT   334.87 (+1.29%)
FB   317.19 (-2.24%)
GOOGL   2,876.81 (+1.37%)
AMZN   3,490.12 (-0.48%)
TSLA   1,135.00 (-0.85%)
NVDA   321.98 (-1.46%)
BABA   124.98 (-2.00%)
NIO   39.45 (+0.82%)
CGC   10.27 (-4.11%)
AMD   152.20 (-3.90%)
GE   95.14 (+0.16%)
MU   87.07 (+3.65%)
T   22.44 (-1.71%)
F   19.94 (+3.91%)
DIS   144.58 (-0.22%)
PFE   54.82 (+2.03%)
ACB   6.18 (-3.74%)
AMC   31.07 (-8.46%)
BA   192.97 (-2.47%)
S&P 500   4,579.02 (+0.26%)
DOW   34,489.97 (+0.02%)
QQQ   394.63 (+0.21%)
AAPL   168.03 (+1.65%)
MSFT   334.87 (+1.29%)
FB   317.19 (-2.24%)
GOOGL   2,876.81 (+1.37%)
AMZN   3,490.12 (-0.48%)
TSLA   1,135.00 (-0.85%)
NVDA   321.98 (-1.46%)
BABA   124.98 (-2.00%)
NIO   39.45 (+0.82%)
CGC   10.27 (-4.11%)
AMD   152.20 (-3.90%)
GE   95.14 (+0.16%)
MU   87.07 (+3.65%)
T   22.44 (-1.71%)
F   19.94 (+3.91%)
DIS   144.58 (-0.22%)
PFE   54.82 (+2.03%)
ACB   6.18 (-3.74%)
AMC   31.07 (-8.46%)
BA   192.97 (-2.47%)
S&P 500   4,579.02 (+0.26%)
DOW   34,489.97 (+0.02%)
QQQ   394.63 (+0.21%)
AAPL   168.03 (+1.65%)
MSFT   334.87 (+1.29%)
FB   317.19 (-2.24%)
GOOGL   2,876.81 (+1.37%)
AMZN   3,490.12 (-0.48%)
TSLA   1,135.00 (-0.85%)
NVDA   321.98 (-1.46%)
BABA   124.98 (-2.00%)
NIO   39.45 (+0.82%)
CGC   10.27 (-4.11%)
AMD   152.20 (-3.90%)
GE   95.14 (+0.16%)
MU   87.07 (+3.65%)
T   22.44 (-1.71%)
F   19.94 (+3.91%)
DIS   144.58 (-0.22%)
PFE   54.82 (+2.03%)
ACB   6.18 (-3.74%)
AMC   31.07 (-8.46%)
BA   192.97 (-2.47%)
NASDAQ:TTOO

T2 Biosystems Stock Forecast, Price & News

$0.60
-0.02 (-2.71%)
(As of 12/1/2021 01:59 PM ET)
Add
Compare
Today's Range
$0.59
$0.73
50-Day Range
$0.60
$1.01
52-Week Range
$0.59
$3.79
Volume
39,242 shs
Average Volume
6.15 million shs
Market Capitalization
$100.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.18
30 days | 90 days | 365 days | Advanced Chart
Receive TTOO News and Ratings via Email

Sign-up to receive the latest news and ratings for T2 Biosystems and its competitors with MarketBeat's FREE daily newsletter.


T2 Biosystems logo

About T2 Biosystems

T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Headlines

Is T2 Biosystems (NASDAQ:TTOO) Using Debt Sensibly?
October 26, 2021 |  finance.yahoo.com
T2 Biosystems to Unveil New Data at September Conferences
September 14, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TTOO
Employees
148
Year Founded
N/A

Sales & Book Value

Annual Sales
$18.13 million
Book Value
($0.01) per share

Profitability

Net Income
$-46.80 million
Net Margins
-162.84%
Pretax Margin
-162.84%

Debt

Price-To-Earnings

Miscellaneous

Free Float
154,516,000
Market Cap
$100.08 million
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/03/2022

MarketRank

Overall MarketRank

1.63 out of 5 stars

Medical Sector

988th out of 1,392 stocks

Surgical & Medical Instruments Industry

102nd out of 127 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions

Is T2 Biosystems a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" T2 Biosystems stock.
View analyst ratings for T2 Biosystems
or view top-rated stocks.

How has T2 Biosystems' stock been impacted by Coronavirus?

T2 Biosystems' stock was trading at $0.4950 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TTOO stock has increased by 19.9% and is now trading at $0.5934.
View which stocks have been most impacted by COVID-19
.

When is T2 Biosystems' next earnings date?

T2 Biosystems is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for T2 Biosystems
.

How were T2 Biosystems' earnings last quarter?

T2 Biosystems, Inc. (NASDAQ:TTOO) announced its quarterly earnings results on Thursday, November, 4th. The medical equipment provider reported ($0.08) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.08). T2 Biosystems had a negative net margin of 162.84% and a negative trailing twelve-month return on equity of 1,278.55%. During the same period in the prior year, the business earned ($0.08) earnings per share.
View T2 Biosystems' earnings history
.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems updated its FY 2021 earnings guidance on Thursday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $25 million-$27 million, compared to the consensus revenue estimate of $25.02 million.

What price target have analysts set for TTOO?

4 analysts have issued twelve-month target prices for T2 Biosystems' shares. Their forecasts range from $1.65 to $3.50. On average, they expect T2 Biosystems' share price to reach $2.91 in the next year. This suggests a possible upside of 390.8% from the stock's current price.
View analysts' price targets for T2 Biosystems
or view top-rated stocks among Wall Street analysts.

Who are T2 Biosystems' key executives?

T2 Biosystems' management team includes the following people:
  • John J. Sperzel, Chairman, President & Chief Executive Officer
  • Alec Barclay, Chief Operations Officer
  • John M. Sprague, Chief Financial Officer
  • Roger Smith, Vice President-Science, Research & Development
  • Sandy J. Estrada, Vice President-Medical Affairs

What is John McDonough's approval rating as T2 Biosystems' CEO?

36 employees have rated T2 Biosystems CEO John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among T2 Biosystems' employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of T2 Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT).

What is T2 Biosystems' stock symbol?

T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."

Who are T2 Biosystems' major shareholders?

T2 Biosystems' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.77%), Millennium Management LLC (0.98%), Geode Capital Management LLC (0.91%), Natixis (0.32%), Gagnon Securities LLC (0.31%) and GSA Capital Partners LLP (0.10%). Company insiders that own T2 Biosystems stock include Adrian M Jones, Alec Barclay, David B Elsbree, Goldman Sachs & Co Llc, John M Sprague, John Mcdonough, Michael Terrence Gibbs and Thomas J Lowery.
View institutional ownership trends for T2 Biosystems
.

Which institutional investors are selling T2 Biosystems stock?

TTOO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Gagnon Securities LLC, Advisor Group Holdings Inc., Citadel Advisors LLC, BlackRock Inc., and HAP Trading LLC. Company insiders that have sold T2 Biosystems company stock in the last year include Alec Barclay, John M Sprague, John Mcdonough, and Michael Terrence Gibbs.
View insider buying and selling activity for T2 Biosystems
or view top insider-selling stocks.

Which institutional investors are buying T2 Biosystems stock?

TTOO stock was bought by a variety of institutional investors in the last quarter, including Natixis, GSA Capital Partners LLP, Welch & Forbes LLC, Franklin Resources Inc., Geode Capital Management LLC, Barclays PLC, Valeo Financial Advisors LLC, and Geneos Wealth Management Inc.. Company insiders that have bought T2 Biosystems stock in the last two years include Adrian M Jones, and Goldman Sachs & Co Llc.
View insider buying and selling activity for T2 Biosystems
or or view top insider-buying stocks.

How do I buy shares of T2 Biosystems?

Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is T2 Biosystems' stock price today?

One share of TTOO stock can currently be purchased for approximately $0.59.

How much money does T2 Biosystems make?

T2 Biosystems has a market capitalization of $98.49 million and generates $18.13 million in revenue each year. The medical equipment provider earns $-46.80 million in net income (profit) each year or ($0.30) on an earnings per share basis.

How many employees does T2 Biosystems have?

T2 Biosystems employs 148 workers across the globe.

What is T2 Biosystems' official website?

The official website for T2 Biosystems is www.t2biosystems.com.

Where are T2 Biosystems' headquarters?

T2 Biosystems is headquartered at 101 HARTWELL AVENUE, LEXINGTON MA, 02421.

How can I contact T2 Biosystems?

T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at (781) 761-4646, via email at [email protected], or via fax at 781-357-3080.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.